Clarity Pharmaceuticals (ASX:CU6) signed a commercial supply agreement with US-based Nusano for copper-64, a key isotope used along with the company's theranostic radiopharmaceutical SAR-bisPSMA for diagnosing and treating cancer, according to a Thursday filing with the Australian bourse.
Production will start at Nusano's Utah facility this year, with copper-64 deliveries to start in early 2026, the filing said.
The agreement, effective Wednesday, runs for an initial three years with automatic two-year renewals, the filing added.
Financial terms were not disclosed.
Shares of the company rose almost 12% in recent Thursday trade.